Calcineurin, myocardial hypertrophy, and electrical remodeling

Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026

Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

American journal of clinical dermatology·2026

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.

The Journal of dermatology·2026

Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib.

Dermatology and therapy·2026

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.

Dermatology and therapy·2025

A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2025

Free fatty acid receptor 4 in cardiac myocytes ameliorates ischemic cardiomyopathy.

Cardiovascular research·2026

Inflammatory cytokines and immune signalling in heart failure: mechanisms, models and emerging therapies.

Cardiovascular research·2026

Timing of food intake impacts cardiovascular and neuroendocrine physiology and risk of disease.

Cardiovascular research·2026

Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy.

Cardiovascular research·2026

Liver sinusoidal endothelial cell (LSEC) defenestration in chronic heart failure is primarily dependent on cardiac diastolic dysfunction and is reversed by sodium-glucose cotransporter 2 inhibitor but not by angiotensin-converting enzyme inhibitor.

Cardiovascular research·2026

Polycystin-1 suppresses apoptotic signalling in endothelial cells and protects from atherosclerosis.

Cardiovascular research·2026

Patient-Derived Organoid and Single-Cell Multiomics Reveal Evolution Driven by CEACAM6/KRT19-Mediated Heterogeneity.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026

Primary Cardiac Paraganglioma Management and Resection With Rare Recurrent Metastasis.

JACC. Case reports·2026

Emerging therapeutic strategies for triple-negative breast cancer using ruthenium, iridium, and rhenium complexes.

Dalton transactions (Cambridge, England : 2003)·2026

Metal-Phenolic Networks: Emerging Nanoarchitectures for Cancer Therapy.

Angewandte Chemie (International ed. in English)·2026

Intracellular Delivery of Antibody-Based Therapeutics for Targeted Oncogenic c-Myc Degradation in Mammalian Cells and Mice.

Angewandte Chemie (International ed. in English)·2026

Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy.

Haematologica·2026

Related Experiment Videos

Calcineurin, myocardial hypertrophy, and electrical remodeling

Related Concept Videos

Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.

Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.

Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib.

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.

A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making.

Free fatty acid receptor 4 in cardiac myocytes ameliorates ischemic cardiomyopathy.

Inflammatory cytokines and immune signalling in heart failure: mechanisms, models and emerging therapies.

Timing of food intake impacts cardiovascular and neuroendocrine physiology and risk of disease.

Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy.

Liver sinusoidal endothelial cell (LSEC) defenestration in chronic heart failure is primarily dependent on cardiac diastolic dysfunction and is reversed by sodium-glucose cotransporter 2 inhibitor but not by angiotensin-converting enzyme inhibitor.

Polycystin-1 suppresses apoptotic signalling in endothelial cells and protects from atherosclerosis.

Patient-Derived Organoid and Single-Cell Multiomics Reveal Evolution Driven by CEACAM6/KRT19-Mediated Heterogeneity.

Primary Cardiac Paraganglioma Management and Resection With Rare Recurrent Metastasis.

Emerging therapeutic strategies for triple-negative breast cancer using ruthenium, iridium, and rhenium complexes.

Metal-Phenolic Networks: Emerging Nanoarchitectures for Cancer Therapy.

Intracellular Delivery of Antibody-Based Therapeutics for Targeted Oncogenic c-Myc Degradation in Mammalian Cells and Mice.

Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy.

Related Experiment Videos

Calcineurin, myocardial hypertrophy, and electrical remodeling

Related Concept Videos

Related Articles